Shiv Kumar Sarin

Dr. Shiv Kumar Sarin


Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2015 in Hepatology International
Verified
Journal Article
Open access
PDF file
SSShiv Kumar Sarin
Shiv Kumar Sarin
MKM. Kumar
M. Kumar
GLG. K. Lau
G. K. Lau
ZAZ. Abbas
Z. Abbas
HCH. L. Y. Chan
H. L. Y. Chan
JKJia-Horng Kao
Jia-Horng Kao
Worldwide, some 240 million people have chronic hepatitis B virus (HBV), with the highest rates of infection in Africa and Asia. Our understanding of the natural history of HBV infection and the potential for therapy of the resultant disease is continuously improving. New data have become available since the previous APASL guidelines for management of HBV infection were published in 2012. The objective of this manuscript is to update the recommendations for the optimal management of chronic HBV infection. The 2015 guidelines were developed by a panel of Asian experts chosen by the APASL. The clinical practice guidelines are based on evidence from existing publications or, if evidence was unavailable, on the experts’ personal experience and opinion after deliberations. Manuscripts and abstracts of important meetings published through January 2015 have been evaluated. This guideline covers the full spectrum of care of patients infected with hepatitis B, including new terminology, natural history, screening, vaccination, counseling, diagnosis, assessment of the stage of liver disease, the indications, timing, choice and duration of single or combination of antiviral drugs, screening for HCC, management in special situations like childhood, pregnancy, coinfections, renal impairment and pre- and post-liver transplant, and policy guidelines. However, areas of uncertainty still exist, and clinicians, patients, and public health authorities must therefore continue to make choices on the basis of the evolving evidence. The final clinical practice guidelines and recommendations are presented here, along with the relevant background information.

6 June 2019 in Hepatology International
Verified
Journal Article
Open access
PDF file
APAPASL ACLF Research Consortium (AARC) for APASL ACLF working Party.
APASL ACLF Research Consortium (AARC) for APASL ACLF working Party.
SSShiv Kumar Sarin
Shiv Kumar Sarin
ACAshok Choudhury
Ashok Choudhury
MSManoj K. Sharma
Manoj K. Sharma
RMRakhi Maiwall
Rakhi Maiwall
EYEileen L. Yoon
Eileen L. Yoon
The first consensus report of the working party of the Asian Pacific Association for the Study of the Liver (APASL) set up in 2004 on acute-on-chronic liver failure (ACLF) was published in 2009. With international groups volunteering to join, the “APASL ACLF Research Consortium (AARC)” was formed in 2012, which continued to collect prospective ACLF patient data. Based on the prospective data analysis of nearly 1400 patients, the AARC consensus was published in 2014. In the past nearly four-and-a-half years, the AARC database has been enriched to about 5200 cases by major hepatology centers across Asia. The data published during the interim period were carefully analyzed and areas of contention and new developments in the field of ACLF were prioritized in a systematic manner. The AARC database was also approached for answering some of the issues where published data were limited, such as liver failure grading, its impact on the ‘Golden Therapeutic Window’, extrahepatic organ dysfunction and failure, development of sepsis, distinctive features of acute decompensation from ACLF and pediatric ACLF and the issues were analyzed. These initiatives concluded in a two-day meeting in October 2018 at New Delhi with finalization of the new AARC consensus. Only those statements, which were based on evidence using the Grade System and were unanimously recommended, were accepted. Finalized statements were again circulated to all the experts and subsequently presented at the AARC investigators meeting at the AASLD in November 2018. The suggestions from the experts were used to revise and finalize the consensus. After detailed deliberations and data analysis, the original definition of ACLF was found to withstand the test of time and be able to identify a homogenous group of patients presenting with liver failure. New management options including the algorithms for the management of coagulation disorders, renal replacement therapy, sepsis, variceal bleed, antivirals and criteria for liver transplantation for ACLF patients were proposed. The final consensus statements along with the relevant background information and areas requiring future studies are presented here.

1 October 2020 in Hepatology International
Verified
Journal Article
Open access
PDF file
MEMohammed Eslam
Mohammed Eslam
SSShiv Kumar Sarin
Shiv Kumar Sarin
VWVincent Wai-Sun Wong
Vincent Wai-Sun Wong
JFJian-Gao Fan
Jian-Gao Fan
TKTakumi Kawaguchi
Takumi Kawaguchi
JGJacob George
Jacob George
Metabolic associated fatty liver disease (MAFLD) is the principal worldwide cause of liver disease and affects nearly a quarter of the global population. The objective of this work was to present the clinical practice guidelines of the Asian Pacific Association for the Study of the Liver (APASL) on MAFLD. The guidelines cover various aspects of MAFLD including its epidemiology, diagnosis, screening, assessment, and treatment. The document is intended for practical use and for setting the stage for advancing clinical practice, knowledge, and research of MAFLD in adults, with specific reference to special groups as necessary. The guidelines also seek to improve patient care and awareness of the disease and assist stakeholders in the decision-making process by providing evidence-based data. The guidelines take into consideration the burden of clinical management for the healthcare sector.

27 October 2021 in Nature Reviews Gastroenterology & Hepatology
Verified
Journal Article
Closed access
PDF file
JLJeffrey Lazarus
Jeffrey Lazarus
HMHenry E. Mark
Henry E. Mark
QAQuentin M. Anstee
Quentin M. Anstee
JAJuan Pablo Arab
Juan Pablo Arab
RBRachel L. Batterham
Rachel L. Batterham
SZShira Zelber-Sagi
Shira Zelber-Sagi

20 November 2008 in Hepatology International
Verified
Journal Article
Open access
PDF file
SSShiv Kumar Sarin
Shiv Kumar Sarin
AKAshish Kumar
Ashish Kumar
JAJohn A. Almeida
John A. Almeida
YCYogesh Kumar Chawla
Yogesh Kumar Chawla
SFSheung Tat Fan
Sheung Tat Fan
MYMan-Fung Yuen
Man-Fung Yuen
The Asian Pacific Association for the Study of the Liver (APASL) set up a working party on acute-on-chronic liver failure (ACLF) in 2004, with a mandate to develop consensus guidelines on various aspects of ACLF relevant to disease patterns and clinical practice in the Asia-Pacific region. Experts predominantly from the Asia–Pacific region constituted this working party and were requested to identify different issues of ACLF and develop the consensus guidelines. A 2-day meeting of the working party was held on January 22–23, 2008, at New Delhi, India, to discuss and finalize the consensus statements. Only those statements that were unanimously approved by the experts were accepted. These statements were circulated to all the experts and subsequently presented at the Annual Conference of the APASL at Seoul, Korea, in March 2008. The consensus statements along with relevant background information are presented in this review.

26 September 2014 in Hepatology International
Verified
Journal Article
Open access
PDF file
SSShiv Kumar Sarin
Shiv Kumar Sarin
CKChandan Kumar Kedarisetty
Chandan Kumar Kedarisetty
ZAZaigham Abbas
Zaigham Abbas
DADeepak Amarapurkar
Deepak Amarapurkar
CBChhagan Bihari
Chhagan Bihari
TPThe Apasl Aclf Working Party
The Apasl Aclf Working Party
The first consensus report of the working party of the Asian Pacific Association for the Study of the Liver (APASL) set up in 2004 on acute-on-chronic liver failure (ACLF) was published in 2009. Due to the rapid advancements in the knowledge and available information, a consortium of members from countries across Asia Pacific, “APASL ACLF Research Consortium (AARC),” was formed in 2012. A large cohort of retrospective and prospective data of ACLF patients was collated and followed up in this data base. The current ACLF definition was reassessed based on the new AARC data base. These initiatives were concluded on a 2-day meeting in February 2014 at New Delhi and led to the development of the final AARC consensus. Only those statements which were based on the evidence and were unanimously recommended were accepted. These statements were circulated again to all the experts and subsequently presented at the annual conference of the APASL at Brisbane, on March 14, 2014. The suggestions from the delegates were analyzed by the expert panel, and the modifications in the consensus were made. The final consensus and guidelines document was prepared. After detailed deliberations and data analysis, the original proposed definition was found to withstand the test of time and identify a homogenous group of patients presenting with liver failure. Based on the AARC data, liver failure grading, and its impact on the "Golden therapeutic Window," extra-hepatic organ failure and development of sepsis were analyzed. New management options including the algorithms for the management of coagulation disorders, renal replacement therapy, sepsis, variceal bleed, antivirals, and criteria for liver transplantation for ACLF patients were proposed. The final consensus statements along with the relevant background information are presented here.